NovoCure Limited NVCR
11.10 USD -0.20 (-1.76%)
As ofNov 17, 2026, 2:51 PM EST
11.07 Day range 11.51
9.82 52-week range 21.45
- YTD
- -14.15%
- 1 year
- -1.50%
News
benzinga.com NovoCure Announces Publication Of Data Analysis From Phase 3 PANOVA-3 Trial Novocure (NASDAQ:NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields)…
businesswire.com JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial…benzinga.com Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31 Ladenburg Thalmann analyst Kevin DeGeeter maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $27 to $31.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 13.9% to $2.2 during Tuesday's after-market session. The company's market cap stands at $73.3 million. Longeveron (NASDAQ:LGVN) stock…
fool.com FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors. Mya is an investigational product in the Optune line. These wearable devices generate electric fields that disrupt cell division, ideally preventing the spread of cancer.benzinga.com Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $19 Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and lowers the price target from $20 to $19.
benzinga.com Novocure Stock Slips After FDA Rejects Its Cancer Treatment Device Novocure receives an FDA Not Approvable Letter for Optune Mya in NSCLC brain metastases, citing unclear clinical benefit while finding no safety issues.benzinga.com Novocure Receives Not Approvable Letter From FDA In Response To PMA Application For Optune Mya For Treatment Of Adult Patients With Brain Metastases From Non-Small Cell Lung Cancer Following Stereotactic Radiation Novocure (NASDAQ:NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune…
benzinga.com Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15 Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Equal-Weight and lowers the price target from $20 to $15.
benzinga.com Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20 Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a Outperform and lowers the price target from $23 to $20.
benzinga.com NovoCure Q3 2026 Earnings Call Transcript NovoCure (NASDAQ:NVCR) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com NovoCure Q3 EPS $(0.09) Beats $(0.24) Estimate, Sales $193.399M Beat $182.233M Estimate NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.24) by 62.5 percent. This is a 72.73 percent increase over losses of $(0.33) per…
benzinga.com NovoCure Raises FY2026 Sales Guidance from $710.000M-$725.000M to $736.000M-$743.000M vs $725.814M Est NovoCure (NASDAQ:NVCR) raises FY2026 sales outlook from $710.000 million-$725.000 million to $736.000 million-$743.000 million vs $725.814 million estimate.
